Henan Lingrui Pharmaceutical (600285) Stock Overview
Engages in the research, development, production, and sale of drugs in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
600285 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Henan Lingrui Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥21.08 |
| 52 Week High | CN¥24.94 |
| 52 Week Low | CN¥20.30 |
| Beta | 0.13 |
| 1 Month Change | -4.96% |
| 3 Month Change | 0.67% |
| 1 Year Change | -7.58% |
| 3 Year Change | 31.67% |
| 5 Year Change | 132.41% |
| Change since IPO | 571.67% |
Recent News & Updates
Recent updates
Are Investors Undervaluing Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) By 38%?
Mar 27
Does Henan Lingrui Pharmaceutical (SHSE:600285) Deserve A Spot On Your Watchlist?
Jan 07Does Henan Lingrui Pharmaceutical (SHSE:600285) Have A Healthy Balance Sheet?
Nov 30An Intrinsic Calculation For Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Suggests It's 44% Undervalued
Oct 28Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Surges 33% Yet Its Low P/E Is No Reason For Excitement
Oct 13If EPS Growth Is Important To You, Henan Lingrui Pharmaceutical (SHSE:600285) Presents An Opportunity
Aug 07A Look At The Fair Value Of Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285)
Jul 03Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Stock Catapults 27% Though Its Price And Business Still Lag The Market
May 07Henan Lingrui Pharmaceutical's (SHSE:600285) Earnings May Just Be The Starting Point
May 02Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Held Back By Insufficient Growth Even After Shares Climb 27%
Mar 04Should You Be Adding Henan Lingrui Pharmaceutical (SHSE:600285) To Your Watchlist Today?
Feb 29Shareholder Returns
| 600285 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -2.8% | -0.5% | 2.7% |
| 1Y | -7.6% | 12.9% | 35.3% |
Return vs Industry: 600285 underperformed the CN Pharmaceuticals industry which returned 14.2% over the past year.
Return vs Market: 600285 underperformed the CN Market which returned 34.9% over the past year.
Price Volatility
| 600285 volatility | |
|---|---|
| 600285 Average Weekly Movement | 2.8% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in CN Market | 9.9% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 600285 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600285's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 2,435 | Wei Xiong | www.lingrui.com |
Henan Lingrui Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China. It operates through Pharmaceutical and Healthcare Division; and Others segments. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, and tinctures, etc. for various indications, including orthopedic, cardiovascular, cerebrovascular, dermatology, pediatrics, respiratory, and anesthesiology.
Henan Lingrui Pharmaceutical Co., Ltd. Fundamentals Summary
| 600285 fundamental statistics | |
|---|---|
| Market cap | CN¥11.87b |
| Earnings (TTM) | CN¥799.61m |
| Revenue (TTM) | CN¥3.78b |
Is 600285 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600285 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.78b |
| Cost of Revenue | CN¥735.96m |
| Gross Profit | CN¥3.05b |
| Other Expenses | CN¥2.25b |
| Earnings | CN¥799.61m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Apr 28, 2026
| Earnings per share (EPS) | 1.42 |
| Gross Margin | 80.55% |
| Net Profit Margin | 21.14% |
| Debt/Equity Ratio | 15.7% |
How did 600285 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/17 15:03 |
| End of Day Share Price | 2026/04/17 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Henan Lingrui Pharmaceutical Co., Ltd. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yang Luo | CLSA |
| Charlotte Zhan | CLSA |
| Wenxin Yu | Haitong International Research Limited |